Variagenics Finds Way to Analyze Effects of SNPs | GenomeWeb

NEW YORK, March 23 – SNP-detection company Variagenics of Cambridge, Mass., said Friday it has developed a way to analyze the functional impacts of certain SNPs.

The findings have been published in this week’s issue of the Journal of Molecular
Biology, which describes the computational method for predicting functional consequences of non-synonymous SNPs. These SNPs cause amino acid substitutions in proteins and are less prevalent than synoymous SNPs, or the polymorphisms in protein encoding regions that do not affect protein sequence.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.